Available Trials
A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.
Bladder
-
SKB264 with pembrolizumab in subjects with selected solid tumors
A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
-
IMMU-132 for Metastatic Urothelial Cancer
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
Breast
-
DB-1303 vs. SOC in HER2low, HER+ Metastatic breast cancer
A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy
-
Adjuvant Sacituzumab Govitecan & Pembrolizumab vs. SOC tx in patients with TNBC
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
-
Camizestrant vs. Endorine Therapy as Adjuvant Treatment in Early Breast cancer
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
-
Observational Study of metastatic breast cancer patients
A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)
-
Dato-DXd +/- Durvalumab vs. Investigator’s choice in Triple Neg Breast Ca
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
-
Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients
Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
-
Phase 3 Study of Adjuvant Endocrine Therapy vs. Imlunestrant
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
-
Phase III Study Comparing Gedatolisib + Palbociclib & Fulvestrant to SOC treatments in Breast Ca
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Colon
-
Phase 3 study of MRTX849 + Cetuximab vs. Chemo in patients with colon cancer w/KRAS G12C mutation
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
-
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Gastrointestinal
-
Futibatinib with PD-1 antibody-based SOC patients with solid tumors
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
-
Phase 2 study of Pembro + Lenvatinib + Belzutifan in Solid Tumors
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors
Head and Neck
-
Tislelizumab in Combination with Investigational Agents as treatment in patients with Head & Neck Ca
A Randomized, Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BGB-HNSCC-201)
Lung
-
GDC-6036 in combination w/other anti-cancer therapies in untreated metastatic NSCLC w/KRAS G12C mut
A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation
-
A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer
A Phase 2 Study of Alisertib in Patients with Extensive Small Cell Lung Cancer
-
SGN-B6A compared with docetaxel in previously treated NSCLC
A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer
-
Furmonertinib vs. Platinum-Chemo as 1st line treatment for NSCLC
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
-
Avutometinib + Sotorasib in Patients with KRAS G12C mutant NSCLC
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
-
AB122 + AB154 vs. Pembrolizumab in 1st line PDL1- High NSCLC
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC
Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC
-
Multiple Therapies according to biomarker status in patients with Lung Cancer
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with locally advanced, unresectable, Stage III Non-Small Cell Lung Cancer
-
Screening Study to determine biomarker status for patients with malignant tumors
Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors
-
Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Lymphoma
-
Epcoritamab for DLBCL or FL
Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a): Epcoritamab in Outpatient Setting
-
Stage 3 study of Tazemetostat/placebo + Lenalidomide and Rituximab in Patients with FL
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)
Melanoma
-
Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors
A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
Ovarian
-
SKB264 with pembrolizumab in subjects with selected solid tumors
A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Pancreatic
-
Futibatinib with PD-1 antibody-based SOC patients with solid tumors
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
-
BI 907872 in locally advanced/metastatic disease with MDM2 amplified, TP53 wild-type solid tumors
A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.
Prostate
-
Trials for high risk prostate cancer evaluating de-intensification and intensification w/radiation
Parallel Phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation
-
MK-5684 vs Abiraterone or Enzalutamide in patients with mCRPC who have progressed on 1 prior NHA
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) and Have Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
-
MK-5684 vs. Abiraterone or Enzalutamide in pts w/mCRPC
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
-
Apalutamide with Androgen-Deprivation Therapy in Metastatic Castration-Sensitive Prostate Ca
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020)
Solid Tumors
-
Futibatinib with PD-1 antibody-based SOC patients with solid tumors
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
-
SKB264 with pembrolizumab in subjects with selected solid tumors
A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
-
BI 907872 in locally advanced/metastatic disease with MDM2 amplified, TP53 wild-type solid tumors
A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.
-
Trial of Nab-Sirolimus for patients with malignant solid tumors with TSC1 or TSC2 alterations
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)